<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/33919BC4-1979-4EA8-AE27-AC121993DE74"><gtr:id>33919BC4-1979-4EA8-AE27-AC121993DE74</gtr:id><gtr:name>Royal College of General Practioners (RCGP)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9F7B66FB-D196-494A-962D-58D4771534C5"><gtr:id>9F7B66FB-D196-494A-962D-58D4771534C5</gtr:id><gtr:name>Slimming World</gtr:name><gtr:address><gtr:line1>Clover Nook Road</gtr:line1><gtr:line2>Somercotes</gtr:line2><gtr:postCode>DE55 4RF</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/295D7E7B-BDEB-44AD-BB56-85976FD6C05D"><gtr:id>295D7E7B-BDEB-44AD-BB56-85976FD6C05D</gtr:id><gtr:name>Rosemary Conley Diet and Fitness Clubs</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1B6AFD89-3086-4DDD-B0E5-FA77B9C89C88"><gtr:id>1B6AFD89-3086-4DDD-B0E5-FA77B9C89C88</gtr:id><gtr:name>Polish Ministry of Health</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Epidemiology and Public Health</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/33919BC4-1979-4EA8-AE27-AC121993DE74"><gtr:id>33919BC4-1979-4EA8-AE27-AC121993DE74</gtr:id><gtr:name>Royal College of General Practioners (RCGP)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/86BA0D2C-1895-41C5-B18C-092178DFFB3E"><gtr:id>86BA0D2C-1895-41C5-B18C-092178DFFB3E</gtr:id><gtr:name>National Institute for Health Research</gtr:name><gtr:address><gtr:line1>NIHR Clinical Research Network CC</gtr:line1><gtr:line2>Fairbairn House</gtr:line2><gtr:line3>71-75 Clarendon Road</gtr:line3><gtr:postCode>LS2 9PH</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9F7B66FB-D196-494A-962D-58D4771534C5"><gtr:id>9F7B66FB-D196-494A-962D-58D4771534C5</gtr:id><gtr:name>Slimming World</gtr:name><gtr:address><gtr:line1>Clover Nook Road</gtr:line1><gtr:line2>Somercotes</gtr:line2><gtr:postCode>DE55 4RF</gtr:postCode><gtr:region>East Midlands</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/295D7E7B-BDEB-44AD-BB56-85976FD6C05D"><gtr:id>295D7E7B-BDEB-44AD-BB56-85976FD6C05D</gtr:id><gtr:name>Rosemary Conley Diet and Fitness Clubs</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1B6AFD89-3086-4DDD-B0E5-FA77B9C89C88"><gtr:id>1B6AFD89-3086-4DDD-B0E5-FA77B9C89C88</gtr:id><gtr:name>Polish Ministry of Health</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/583583E2-A030-4D55-BFAD-7AE718DAD7A8"><gtr:id>583583E2-A030-4D55-BFAD-7AE718DAD7A8</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Aveyard</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/63568140-464A-4852-A561-948F5C0E8C43"><gtr:id>63568140-464A-4852-A561-948F5C0E8C43</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Stapleton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BA3A5015-6B4D-4E1E-8E58-B5E0E2EA5315"><gtr:id>BA3A5015-6B4D-4E1E-8E58-B5E0E2EA5315</gtr:id><gtr:firstName>Witold</gtr:firstName><gtr:surname>Zatonski</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C3A9CC6E-3BD6-46D3-B3E5-DDD917C92E31"><gtr:id>C3A9CC6E-3BD6-46D3-B3E5-DDD917C92E31</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:otherNames>Jeremy</gtr:otherNames><gtr:surname>West</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/2C4C2D51-38EF-4035-8FE7-1E53CED83C04"><gtr:id>2C4C2D51-38EF-4035-8FE7-1E53CED83C04</gtr:id><gtr:firstName>Magda</gtr:firstName><gtr:surname>Cedzynska</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0501300"><gtr:id>A91F22FE-0C9B-4D4F-AFEE-7A2710C8721B</gtr:id><gtr:title>The effect of Tabex (cytisine) on success of attempts to stop smoking</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0501300</gtr:grantReference><gtr:abstractText>Promoting smoking cessation is probably the single most important goal in reducing cancer. There are several drugs that can help, and psychological support is also effective. There is an opportunity to evaluate a drug (Tabex) that has been in use in Eastern Europe for many years, is generic and cheap to manufacture ? so much so that it costs less than one fifth of current medications. This would be of considerable benefit to UK smokers, the NHS and perhaps more importantly to low income smokers overseas. The proposed rigorous trial would be conducted in Poland and would represent exceptional value for money.

The findings will be taken forward through discussion with the MHRA and other relevant regulatory bodies to establish a basis for licensing. The results will also be dissemintated through appropriate press offices once a paper has been punlished in an appropriate peer review journal.</gtr:abstractText><gtr:technicalSummary>This is a placebo-controlled RCT of Tabex (cytisine) as an aid to smoking cessation. Tabex currently has a licence as a stop smoking medication in some countries in Eastern Europe and has undergone Phase I, Phase II studies and clinical trials. However, the clinical evidence is not sufficient to permit firm conclusions to be made about efficacy or for a licence to be granted in countires such as the UK or US. A recent uncontrolled study in Poland found 12-month continuous abstinence rates, verified by expired air CO, of 18% with minimal behavioural support. This compares favourably with success rates using nicotine replacement therapy. Tabex is very inexpensive and offers the prospect of a treatment costing a small fraction of that currently available. 720 smokers of 10 or more cigarettes per day who are not contra-indicated for the medication would receive Tabex or matching placebo. The primary outcome measure would be 6-months? continuous abstinence verified by expired-air CO.</gtr:technicalSummary><gtr:fund><gtr:end>2011-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>223432</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Slimming World</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Research Development</gtr:department><gtr:description>Slimming World</gtr:description><gtr:id>BC338590-E6D6-4386-9214-DB2E6E60F221</gtr:id><gtr:impact>There are no outputs yet.</gtr:impact><gtr:outcomeId>ipb1Tf1eKEx-1</gtr:outcomeId><gtr:partnerContribution>Slimming world offered to cover the treatment costs for the trial and provided, for free, the vouchers for our participants to attend Slimming World.</gtr:partnerContribution><gtr:piContribution>The research team has taken the lead in designing and getting the trial up and running. We also manage the trial on a daily basis and are responsible for publication and dissemination of results.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute for Health Research</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School for Primary Care Research</gtr:department><gtr:description>Primary Care Research Network (PCRN)</gtr:description><gtr:id>8B5CF6CA-1859-459B-A40F-9BBE53A35986</gtr:id><gtr:impact>Aided practice and participant recruitment in the rapid reduction trial.</gtr:impact><gtr:outcomeId>c6WLwtr7NCn-1</gtr:outcomeId><gtr:partnerContribution>The primary care research network provide support for research in three ways:
1) Providing participating GP surgeries with Service Support Costs to compensate them for taking part in the research
2) Helping to recruit GP practices to take part
3) Providing nursing time to run the study</gtr:partnerContribution><gtr:piContribution>The research is designed to improve knowledge of optimum stop smoking interventions and so will hopefully benefit the NHS.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Human Nutrition Research Unit</gtr:department><gtr:description>MRC Cambridge</gtr:description><gtr:id>0F987A62-1248-4B95-8BAB-03738991260C</gtr:id><gtr:impact>The output is the trial.</gtr:impact><gtr:outcomeId>m31Fd7UEQkR-1</gtr:outcomeId><gtr:partnerContribution>Professor Susan Jebb provides intellectual input for the trial; she has done so from the planning stages and continues to provide support to the trial. She brings expertise surrounding weight management in primary care. The collaboration with the MRC unit ended in 2013 due to Prof Susan Jebb taking up a position at University of Oxford.</gtr:partnerContribution><gtr:piContribution>The research team has taken the lead in designing and getting the trial up and running. We also manage the trial on a daily basis and are responsible for publication and dissemination of results.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal College of General Practitioners</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>RCGP</gtr:description><gtr:id>0089EF23-B7D9-4643-AACE-A4DE5302DBA9</gtr:id><gtr:impact>The training material for the GPs is the output of this collaboration.</gtr:impact><gtr:outcomeId>GeZ6D8m2dtw-1</gtr:outcomeId><gtr:partnerContribution>Dr Rachel Pryke from RCGP assisted with the training materials for the GPs. She is the obesity champion for the RCGP.</gtr:partnerContribution><gtr:piContribution>The research team has taken the lead in designing and getting the trial up and running. We also manage the trial on a daily basis and are responsible for publication and dissemination of results.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Rosemary Conley Diet and Fitness Clubs</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Rosemary Conley</gtr:description><gtr:id>CADDCCC8-00B2-491F-AE85-27B0A6A28F22</gtr:id><gtr:impact>There are no outputs yet.</gtr:impact><gtr:outcomeId>DLU4LfJcgpf-1</gtr:outcomeId><gtr:partnerContribution>Rosemary Conley have provided support for the treatment costs of the trial and some of their class providers have offered to give classes for free to our participants.</gtr:partnerContribution><gtr:piContribution>The research team has taken the lead in designing and getting the trial up and running. We also manage the trial on a daily basis and are responsible for publication and dissemination of results.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Polish Ministry of Health</gtr:collaboratingOrganisation><gtr:country>Poland, Republic of</gtr:country><gtr:department>The Maria Sklodowska-Curie Institute of Oncology</gtr:department><gtr:description>UCL-Warsaw</gtr:description><gtr:id>1BCBD663-70B5-452E-8D0B-C235B2736FA9</gtr:id><gtr:impact>Published paper in NEJM.</gtr:impact><gtr:outcomeId>n4yDd2SLctM-1</gtr:outcomeId><gtr:partnerContribution>Treatment of clinical trial participants</gtr:partnerContribution><gtr:piContribution>Design, management or clinical trial</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Primary Care Clinical Sciences</gtr:department><gtr:description>University of Birmingham</gtr:description><gtr:id>C974DE96-B978-4CB9-8268-9637470A59EE</gtr:id><gtr:impact>The outcome from this partnership is the trial itself.</gtr:impact><gtr:outcomeId>GBc1mt9ArzY-1</gtr:outcomeId><gtr:partnerContribution>Dr Amanda Farley, Dr Amanda Daley, Prof Kate Jolly And Dr Peymane Adab all contributed to this trial from the planning stages and continue to provide support to the trial in a number of capacities, such as intellectual input and trial support.</gtr:partnerContribution><gtr:piContribution>The research team has taken the lead in designing and getting the trial up and running. We also manage the trial on a daily basis and are responsible for publication and dissemination of results.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>A blog in the Conversation</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>52A256E1-FB31-4DB7-8E01-F0A7389FEF45</gtr:id><gtr:impact>A post-doctoral researcher in the team wrote a blog in the Conversation about cytisine and the failure of the world to take this clearly effective medication and make it widely available.</gtr:impact><gtr:outcomeId>58c033bc61cbd4.58604645</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>DH</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>9656C883-D77F-43DC-9965-0806E7AE643E</gtr:id><gtr:impact>Meetings with DH civil servants and ministers

Ongoing considerations of trial results</gtr:impact><gtr:outcomeId>hYFTJbfuRYd</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Cytisine is a very inexpensive medication for smoking cessation. Following this trial it has been put forward for regulatory approval in a number of countries.</gtr:description><gtr:id>6721B4A1-F97C-456A-8F56-5455554B69EC</gtr:id><gtr:impact>Following this trial it has been put forward for regulatory approval in a number of countries.</gtr:impact><gtr:outcomeId>WQQ8VbSW6pN</gtr:outcomeId><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development_distribution</gtr:status><gtr:title>Tabex</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2011</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Clinical trial data</gtr:description><gtr:id>DD16407B-32AB-43EA-9270-6E51E6C7A88A</gtr:id><gtr:impact>Data likely to be of value to drug regulators or pharmaceutical industry</gtr:impact><gtr:outcomeId>av4SmzLgKf1</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>TASC database</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">G0501300</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>A77DAE3A-499B-4F46-971D-6C82F51F9C2E</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>Stroke</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>4F7FE31F-D266-4FE9-9BAB-3D21E9B789BA</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.3  Nutrition and chemoprevention</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>